ACADIA PHARMACEUTICALS INC

Listed Company

ACADCIK 0001070494NasdaqLarge AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$1.07B

Net Income

$391.00M

Total Assets

$1.56B

Equity

$1.23B

Shares Out

171.24M

Op. Cash Flow

$109.84M

ACAD$25.60+13.40% · past yearDBEQ Basic

Daily closing prices

Business

Acadia Pharmaceuticals is a biopharmaceutical company developing medicines for neurological and rare disease conditions. Its commercial products include NUPLAZID (pimavanserin) for Parkinson's disease psychosis and DAYBUE (trofinetide) for Rett syndrome. The company is advancing remlifanserin for Alzheimer's disease psychosis and Lewy Body dementia psychosis, along with earlier-stage programs in essential tremor, tardive dyskinesia, and major depressive disorder. Acadia markets primarily in the United States and is pursuing regulatory approvals and commercialization in Europe, Canada, Israel, and Japan.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	1,072	958	726	517	484
Cost of product sales	89	82	42	10	19
Research and development	329	303	352	362	239
Selling, general and administrative	549	488	407	369	396
Gain on sale of non-financial asset	0	−147	0	0	—
Total operating expenses	967	727	800	741	655
Income (loss) from operations	105	231	−73	−224	−170
Interest income, net	32	25	17	7	591,000
Other income	2	2	5	4	2
Income (loss) before income taxes	139	258	−51	−213	−168
Income tax (benefit) expense	−252	32	10	3	351,000
Consolidated net income	391	226	−61	−216	−168
Earnings (net loss) per share, Basic	2.32	1.37	−0.37	−1.34	−1.05
Earnings (net loss) per share, diluted	2.3	1.36	−0.37	−1.34	−1.05
Weighted average common shares outstanding, basic	168	166	164	162	160,493
Weighted average common shares outstanding, diluted	170	166	164	162	160,493

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	178	320	189	115	147
Investment securities, available-for-sale	642	436	250	302	373
Accounts receivable, net	121	99	98	62	64
Interest and other receivables	27	6	4	885,000	978,000
Inventory	35	22	36	7	8
Prepaid expenses	60	56	39	21	24
Total current assets	1,062	938	616	508	618
Property and equipment, net	8	4	5	6	8
Operating lease right-of-use assets	47	47	52	56	58
Intangible assets, net	109	120	65	0	—
Restricted cash	8	9	6	6	6
Long-term inventory	77	70	5	5	6
Deferred tax assets	250	0	—	—	—
Other assets	4	359,000	476,000	8	4
Total assets	1,564	1,188	749	588	700
Accounts payable	11	16	18	13	7
Accrued liabilities	266	379	237	113	89
Total current liabilities	277	395	254	126	96
Operating lease liabilities	41	42	48	53	56
Other long-term liabilities	19	18	15	9	7
Total liabilities	337	455	317	187	159
Commitments and contingencies (Note 9)	—	—	—	—	—
Preferred stock, $0.0001 par value; 5,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024	0	0	0	0	0
Common stock, $0.0001 par value; 225,000,000 shares authorized at December 31, 2025 and 2024; 170,309,376 shares and 166,708,856 shares issued and outstanding at December 31, 2025 and 2024, respectively	16,000	16,000	16,000	16,000	16,000
Additional paid-in capital	3,039	2,937	2,863	2,771	2,695
Accumulated deficit	−1,813	−2,204	−2,431	−2,370	−2,154
Accumulated other comprehensive income	1	292,000	24,000	−975,000	−192,000
Total stockholders equity	1,227	733	432	400	541
Total liabilities and stockholders equity	1,564	1,188	749	588	700

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net income (loss)	391	226	−61	−216	−168
Stock-based compensation	52	67	66	68	64
Amortization of premiums and accretion of discounts on investment securities	−5	−9	−8	−3	2
Amortization of intangible assets	11	15	4	0	1
Gain on sale of non-financial asset	0	−147	0	0	—
Gain on strategic investment	0	0	−5	−4	−2
Depreciation	900,000	900,000	2	2	2
Loss on sale of investment securities	0	0	524,000	0	0
Deferred income taxes (including benefit from valuation allowance)	−250	0	0	—	—
Accounts receivable, net	−23	−472,000	−36	2	−16
Interest and other receivables	−21	−2	−3	93,000	1
Inventory	−18	−50	−29	2	−4
Prepaid expenses and other current assets	−4	−17	−18	2	2
Operating lease right-of-use assets	9	8	6	7	6
Other assets	−3	117,000	−33,000	−48,000	10,000
Accounts payable	−5	−1	5	6	−2
Accrued liabilities	−19	71	93	24	−8
Operating lease liabilities	−7	−8	−6	−8	−5
Long-term liabilities	1	3	6	2	2
Net cash provided by operating activities	110	158	17	−114	−126
Purchases of investment securities	−693	−505	−370	−363	−493
Sale and maturity of investment securities	494	329	430	436	423
Proceeds from sale of non-financial asset	0	147	0	0	—
Proceeds from sales of strategic investment	0	0	12	0	0
Net purchases of property and equipment	−5	−523,000	−50,000	0	−1
Payment of milestone and contingent payments in connection with asset acquisition	−99	0	−40	0	0
Net cash (used in) provided by investing activities	−303	−31	32	73	−71
Proceeds from issuance of common stock, net of issuance costs	50	7	25	8	18
Net cash provided by financing activities	50	7	25	8	18
Effect of exchange rate changes on cash	26,000	−94,000	−18,000	6,000	7,000
Net (decrease) increase in cash, cash equivalents and restricted cash	−143	134	74	−33	−179
Cash paid for income taxes	25	20	6	2	1
Accrued inventory purchases	1	1	0	0	—
Stock based compensation capitalized	426,000	425,000	79,000	—	—
Accrued milestone and contingent payments in connection with asset acquisition	0	99	30	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is ACADIA PHARMACEUTICALS INC's CIK number?

ACADIA PHARMACEUTICALS INC's SEC CIK number is 0001070494 (1070494). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find ACADIA PHARMACEUTICALS INC's SEC filings?

All of ACADIA PHARMACEUTICALS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did ACADIA PHARMACEUTICALS INC last report earnings?

ACADIA PHARMACEUTICALS INC (ACAD) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-209253). This is ACADIA PHARMACEUTICALS INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is ACADIA PHARMACEUTICALS INC's most recent earnings 8-K?

ACADIA PHARMACEUTICALS INC's latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001193125-26-209253. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View ACADIA PHARMACEUTICALS INC's latest earnings 8-K →
Look up any company's CIK number →